Alumis ALMS
$3.96 −$0.37 (-8.55%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $4.03 +1.77%
Open$4.24
Prev close$4.33
Day range$3.94 – $4.37
Volume1.79M
Market cap$514.09M
P/E (TTM)–
Dividend yield–
ALMS Stock News
Headlines matching Alumis or the ALMS ticker, most recent first.
- Analysts' Top Healthcare Picks: UniQure (QURE), Alumis Inc. (ALMS)
- Raymond James Maintains Alumis(ALMS.US) With Buy Rating
- Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)
- A Quick Look at Today's Ratings for Alumis(ALMS.US), With a Forecast Between $15 to $37
- Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
- Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
- Alumis(ALMS.US) Director Buys US$10.73 Million in Common Stock
- Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25
- Morgan Stanley Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $39
- Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)
- Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Satellos Bioscience (MSLE) and Alumis Inc. (ALMS)
- Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)
- Stifel Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $44
- Guggenheim Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $34
- Alumis Inc. (ALMS) Receives a Rating Update From a Top Analyst
No comments yet — be the first to weigh in on ALMS.
Sign in to join the discussion.